Therapeutic Drug Monitoring of Isavuconazole—But What about the Critically Ill?
Ripenmeet Salhotra
Keywords :
Antifungal treatment, Isavuconazole, Pharmacokinetics in critically ill, Therapeutic drug monitoring
Citation Information :
Salhotra R. Therapeutic Drug Monitoring of Isavuconazole—But What about the Critically Ill?. Indian J Crit Care Med 2023; 27 (6):454-455.
Data on therapeutic drug monitoring of novel, broad-spectrum, and promising antifungal agent Isavuconazole sheds light on factors associated with subtherapeutic drug levels, however, a few other parameters, which characterize the critically ill patients, if included in the analysis, would have improved the understanding of drugs pharmacokinetics in this subset.
Prayag PS, Soman RN, Panchakshari SP, Ajapuje PS, Mahale NP, Dhupad S, et al. Therapeutic drug monitoring of isavuconazole: Lessons learnt from a real-life setting in a Tertiary Care Center in India. Indian J Crit Care Med 2023;27(4):260–264. DOI: 10.5005/jp-journals-10071-24443.
Charlton M, Thompson JP. Pharmacokinetics in sepsis. BJA Educ. 2019;19(1):7–13. DOI: 10.1016/j.bjae.2018.09.006.
Astellas. Cresemba (isavuconazonium sulfate): Highlights of Prescribing Information. 2015. Available from: https://www.astellas.us/docs/cresemba.pdf.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760–769. DOI: 10.1016/S0140-6736(15)01159-9.
Perez L, Corne P, Pasquier G, Konecki C, Sadek M, Le Bihan C, et al. Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses. J Fungi (Basel) 2023;9(2):211. DOI: 10.3390/jof9020211.
